Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-NRT6020 and 68Ga-NRT6020 in FAP-positive advanced solid tumors
NCT06911489Phase 1Recruiting
- Sponsor
- Chengdu Newray Medical Technology
- Start
- Nov 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 177Lu-NRT6020 and 68Ga-NRT6020 in solid tumor, sponsored by Chengdu Newray Medical Technology. Primary endpoints: Adverse events at 1 year, Dose-limiting toxicity at 42 days and 2 more. Started Nov 2025; status: recruiting.
02
Drugs
177Lu-NRT602068Ga-NRT6020
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06911489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06911489.